Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products > 10418 > 

10418-03-8

Products Categories

Basic Information
CAS No.: 10418-03-8
Name: 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol,17-methyl-, (5a,17b)-
Molecular Structure:
Molecular Structure of 10418-03-8 (2'H-Androst-2-eno[3,2-c]pyrazol-17-ol,17-methyl-, (5a,17b)-)
Formula: C21H32N2O
Molecular Weight: 328.49
Synonyms: 2'H-5a-Androst-2-eno[3,2-c]pyrazol-17b-ol, 17-methyl- (8CI);17-Methyl-5a-androstano[3,2-c]pyrazol-17b-ol;17-Methyl-pyrazolo[4',3':2,3]-5a-androstan-17b-ol;17a-Methyl-17b-hydroxy-5a-androstano(3,2-c)pyrazole;17b-Hydroxy-17-methyl-5a-androstano[3,2-c]pyrazole;Anabol;Androstanazol;Androstanazolestanazol;Estazol;Stanazolol;Stromba;Strombaject;Tevabolin;Win 14833;Winstrol;
EINECS: 233-894-8
Density: 1.129 g/cm3
Melting Point: 242 °C
Boiling Point: 490.8 °C at 760 mmHg
Flash Point: 250.7 °C
Solubility:
Appearance: white to light yellow powder
Hazard Symbols: HarmfulXn,IrritantXi
Risk Codes: 63
Safety: 53-22-36/37/39-36-26
Transport Information:
PSA: 48.91000
LogP: 4.11810
Synthetic route
17β-hydroxy-2-hydroxymethylene-17α-methyl-5α-androstan-3-one

17β-hydroxy-2-hydroxymethylene-17α-methyl-5α-androstan-3-one

10418-03-8

stanozolol

Conditions
ConditionsYield
With hydrazine
10418-03-8

stanozolol

7693-46-1

4-Nitrophenyl chloroformate

tanozolol-4-nitrophenyl-carbonate

Conditions
ConditionsYield
With triethylamine In dichloromethane at 20℃; for 3h; pH=8.5;76.85%
10418-03-8

stanozolol

17,17-dimethyl-18-nor-5α-androst-13(14)-eno<3,2-c>pyrazole

Conditions
ConditionsYield
With hydrogenchloride for 0.25h; Ambient temperature;66%
10418-03-8

stanozolol

124-63-0

methanesulfonyl chloride

107000-35-1

(1S,3aS,3bR,5aS,10aS,10bS,12aS)-8-Methanesulfonyl-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydro-7,8-diaza-dicyclopenta[a,h]phenanthren-1-ol

Conditions
ConditionsYield
With pyridine at 0 - 20℃; for 1h;56%
14660-52-7

ethyl 5-bromovalerate

10418-03-8

stanozolol

A

ethyl-5-{17β-hydroxy-17α-methylpyrazolo[3′,4′:3,2]-5α-androstan-1′-yl}pentanoate

B

ethyl 5-{17α-methyl-17β-hydroxypyrazolo[4′,5′:2,3]-5α-androstan-1′-yl}pentanoate

Conditions
ConditionsYield
With caesium carbonate In N,N-dimethyl-formamide at 80℃; for 5h; Microwave irradiation;A 38%
B 28%
10418-03-8

stanozolol

21085-72-3

1-bromo-2,3,4-tri-O-acetyl-α-D-glucuronic acid methyl ester

A

2′‑[N‑(methyl 2,3,4‑tri‑O‑acetyl‑1‑deoxy‑β‑d‑glucuronosyluronate)]‑17α‑methyl‑5α‑androstano[3,2‑c]pyrazol‑17β‑ol

B

1′‑[N‑(methyl 2,3,4‑tri‑O‑acetyl‑1‑deoxy‑β‑d‑glucuronosyluronate)]‑17α‑methyl‑5α‑androstano[3,2‑c]pyrazol‑17β‑ol

Conditions
ConditionsYield
With mercury(II) cyanide; mercury dibromide In nitromethane; benzene for 3h;A 17%
B 5%
110-86-1

pyridine

10418-03-8

stanozolol

stanozolol 17β-sulfate pyridinium salt

Conditions
ConditionsYield
With chlorosulfonic acid 1.) -5 deg C, 2.) RT, 3 h; Yield given. Multistep reaction;
10418-03-8

stanozolol

Sulfuric acid mono-((1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydro-7,8-diaza-dicyclopenta[a,h]phenanthren-1-yl) ester

Conditions
ConditionsYield
With sulfur trioxide pyridine complex In N,N-dimethyl-formamide for 2h; Ambient temperature;
10418-03-8

stanozolol

145841-85-6, 125636-91-1

17-epistanozolol

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: sulfur trioxide pyridine complex / dimethylformamide / 2 h / Ambient temperature
2: K2CO3 / dimethylformamide; H2O / 72 h
View Scheme
2174-58-5

L-malic acid

10418-03-8

stanozolol

((1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f ]indazol-1-ol)*(S-methylsuccinic acid)

Conditions
ConditionsYield
In methanol Milling;
3641-51-8

2-(R)-methylsuccinic acid

10418-03-8

stanozolol

((1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f ]indazol-1-ol)*2(R-methylsuccinic acid)

Conditions
ConditionsYield
In methanol Milling;
10418-03-8

stanozolol

C21H30N2O

Conditions
ConditionsYield
With titanium(IV) oxide In water; acetonitrile Reagent/catalyst; UV-irradiation;
10418-03-8

stanozolol

1‑deoxy‑1‑(17β‑hydroxy‑17α‑methyl‑5α‑androstano[3,2‑c]pyrazol‑1′‑yl)‑β‑d‑glucopyranuronic acid

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: mercury(II) cyanide; mercury dibromide / nitromethane; benzene / 3 h
2.1: lithium hydroxide monohydrate / methanol; water / 7 h / 20 °C
2.2: amberlite 120 ion resin / 0.25 h
View Scheme
10418-03-8

stanozolol

1‑deoxy‑1‑(17β‑hydroxy‑17α‑methyl‑5α‑androstano[3,2‑c]pyrazol‑2′‑yl)‑β‑d‑glucopyranuronic acid

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: mercury(II) cyanide; mercury dibromide / nitromethane; benzene / 3 h
2.1: lithium hydroxide monohydrate / methanol; water / 6 h / 20 °C
2.2: amberlite 120 ion resin / 0.25 h
View Scheme
10418-03-8

stanozolol

C44H72N6O7S

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: caesium carbonate / N,N-dimethyl-formamide / 5 h / 80 °C / Microwave irradiation
2: sodium hydroxide; methanol / water / 1.5 h / 20 °C
3: benzotriazol-1-ol; dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / N,N-dimethyl-formamide / 5 h / 20 °C / Inert atmosphere
View Scheme
10418-03-8

stanozolol

C43H68N6O8S

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: sodium hydrogencarbonate / water; tetrahydrofuran / 20 °C
2: dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / chloroform / 20 °C
3: tetrabutyl ammonium fluoride / tetrahydrofuran / 100 °C / Microwave irradiation
4: benzotriazol-1-ol; dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / N,N-dimethyl-formamide / 5 h / 20 °C / Inert atmosphere
View Scheme
10418-03-8

stanozolol

C30H43N3O5

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: caesium carbonate / N,N-dimethyl-formamide / 5 h / 80 °C / Microwave irradiation
2: sodium hydroxide; methanol / water / 1.5 h / 20 °C
3: dicyclohexyl-carbodiimide / N,N-dimethyl-formamide / 20 °C
View Scheme
10418-03-8

stanozolol

C26H40N2O3

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: caesium carbonate / N,N-dimethyl-formamide / 5 h / 80 °C / Microwave irradiation
2: sodium hydroxide; methanol / water / 1.5 h / 20 °C
View Scheme
10418-03-8

stanozolol

C26H40N2O3

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: caesium carbonate / N,N-dimethyl-formamide / 5 h / 80 °C / Microwave irradiation
2: sodium hydroxide; methanol / water / 1.5 h / 20 °C
View Scheme
10418-03-8

stanozolol

17α-methyl pyrazolo[3′,4′:3,2]-5α-androstane-17β-yl-hemisuccinate

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: sodium hydrogencarbonate / water; tetrahydrofuran / 20 °C
2: dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / chloroform / 20 °C
3: tetrabutyl ammonium fluoride / tetrahydrofuran / 100 °C / Microwave irradiation
View Scheme
10418-03-8

stanozolol

C44H72N6O7S

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: caesium carbonate / N,N-dimethyl-formamide / 5 h / 80 °C / Microwave irradiation
2: sodium hydroxide; methanol / water / 1.5 h / 20 °C
3: benzotriazol-1-ol; dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / N,N-dimethyl-formamide / 5 h / 20 °C / Inert atmosphere
View Scheme
24424-99-5

di-tert-butyl dicarbonate

10418-03-8

stanozolol

A

Boc-stanozolol

B

C26H40N2O3

Conditions
ConditionsYield
With sodium hydrogencarbonate In tetrahydrofuran; water at 20℃;
24424-99-5

di-tert-butyl dicarbonate

10418-03-8

stanozolol

C35H56N2O6Si

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: sodium hydrogencarbonate / water; tetrahydrofuran / 20 °C
2: dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / chloroform / 20 °C
View Scheme
10418-03-8

stanozolol

C26H38N2O4

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: dmap / dichloromethane / 72 h
2: sodium hydroxide / methanol / 1 h / 20 °C
View Scheme
10418-03-8

stanozolol

1490-25-1

succinic acid monomethylester chloride

A

C26H38N2O4

B

C26H38N2O4

Conditions
ConditionsYield
With dmap In dichloromethane for 2h;
10418-03-8

stanozolol

1490-25-1

succinic acid monomethylester chloride

A

C31H44N2O7

B

C31H44N2O7

Conditions
ConditionsYield
With dmap In dichloromethane for 72h; Overall yield = 90 percent;
  • Display:default sort

    New supplier

This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.

Specification

The systematic name of Stanozolol is (1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-ol. With the CAS registry number 10418-03-8, it is also named as 17-Methyl-2'H-5alpha-androst-2-eno(3,2-c)pyrazol-17beta-ol. The product's categories are pharmaceutical; active pharmaceutical ingredients; biochemistry; steroids. It is white to light yellow powder which was developed by Winthrop Laboratories in 1962. And it is a synthetic anabolic steroid derived from testosterone, and has been approved by the FDA for human use. But in the United States, like other anabolic steroids, stanozolol is classified as a controlled substance under federal regulation.

The other characteristics of this product can be summarized as: (1)ACD/LogP: 5.53; (2)# of Rule of 5 Violations: 1; (3)ACD/LogD (pH 5.5): 5.52; (4)ACD/LogD (pH 7.4): 5.53; (5)ACD/BCF (pH 5.5): 9063.27; (6)ACD/BCF (pH 7.4): 9432.91; (7)ACD/KOC (pH 5.5): 23400.01; (8)ACD/KOC (pH 7.4): 24354.36; (9)#H bond acceptors: 3; (10)#H bond donors: 2; (11)#Freely Rotating Bonds: 1; (12)Index of Refraction: 1.573; (13)Molar Refractivity: 95.87 cm3; (14)Molar Volume: 290.8 cm3; (15)Polarizability: 38×10-24 cm3; (16)Surface Tension: 48.8 dyne/cm; (17)Enthalpy of Vaporization: 79.77 kJ/mol; (18)Vapour Pressure: 1.89E-10 mmHg at 25°C; (19)Tautomer Count: 2; (20)Exact Mass: 328.251464; (21)MonoIsotopic Mass: 328.251464; (22)Topological Polar Surface Area: 48.9; (23)Heavy Atom Count: 24.

Preparation: The pyrazole ring in stanozolol can be prepared by the condensation of a keto-aldehyde with hydrazine.

Uses of Stanozolol: It is used in chronic wasting disease, weight loss of illness and after surgery, elderly and frail, osteoporosis, stunted children, aplastic anemia and so on. Stanozolol is commonly used by athletes and bodybuilders alike to lose fat while retaining lean body mass. Additionly, it is preferred by many steroid users due to the fact that it causes strength increases without excess weight-gain, promotes increases in vascularity, and will not convert to estrogen.

When you are using this chemical, please be cautious about it as the following:
It is possible risk of harm to the unborn child, so people should not breathe dust. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. If you want to contact this product, you must wear suitable protective clothing, gloves and eye/face protection. Additionally, avoid exposure - obtain special instructions before use. 

People can use the following data to convert to the molecule structure. 
1. SMILES:O[C@@]5(C)CC[C@H]4[C@H]3[C@@H]([C@]2(Cc1c(nnc1)C[C@@H]2CC3)C)CC[C@@]45C 
2. InChI:InChI=1/C21H32N2O/c1-19-11-13-12-22-23-18(13)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,24H,4-11H2,1-3H3,(H,22,23)/t14-,15+,16-,17-,19-,20-,21-/m0/s1